Previous 10 | Next 10 |
CytRx Corporation (OTCQB: CYTR) , a biopharmaceutical research and development company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs , according to the company’s website (see here: www.cytrx.com ). In this SNNLive In-Studio...
CytRx Corporation (OTCQB: CYTR) , a biopharmaceutical research and development company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs , according to the company’s website (see here: www.cytrx.com ). In this SNNLive In-Studio...
LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the formulation, s...
DENVER, Colo., June 19, 2019- (24/7MarketNews via COMTEX) Venture Market News for June 19, 2019. Midas Gold Corp. Announces Closing of C$19.9 Million Bought Deal Public Offering VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- Midas Gold Corp. (TSX:MAX, OTCQX:MDRPF) (“Mi...
LOS ANGELES , June 19, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of ...
LOS ANGELES , May 31, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019 , under the same ticke...
CytRx (NASDAQ: CYTR ): Q1 GAAP EPS of -$0.04 beats by $0.02 . Cash and cash equivalents of $9.02M. Shares +1.9% Press Release More news on: CytRx Corporation, Earnings news and commentary, Healthcare stocks news, ,
LOS ANGELES , May 15, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the first quarter ended March 31, 2019 , and provided an overview of recent accomplishmen...
LOS ANGELES , May 8, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of aldoxoru...
LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided clinical guidance on arimoclomol developm...
News, Short Squeeze, Breakout and More Instantly...
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, Octo...
The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceut...
Patent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has...